ClinicalTrials.gg
RecruitingNCT02991365Updated Feb 2, 2024

Effect of Weight Loss on Brain Insulin Sensitivity in Humans

An interventional study of nasal insulin and placebo spray in Insulin Resistance, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Dec 2016; still recruiting 9 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Insulin Resistance by University Hospital Tuebingen — 4 open to participants now, 6 under way, none of them phase 3. Insulin Resistance · University Hospital Tuebingen.

Planned enrollment
6th of 16
40 · median 35
Started
2016
the only one that year
No phase
16 of 19
3 open now
Registered
6th of 19
by date

Among the 19 studies in Insulin Resistance by University Hospital Tuebingen, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 16 with no phase, and was the 6th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

4 of the 19 studies in Insulin Resistance by University Hospital Tuebingen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Insulin Resistance by University Hospital Tuebingen, or all of them as a file.
02

Study summary

Obesity if known to be associated with brain insulin resistance in humans. This condition has not only implication for the brain but also for whole-body energy homeostasis. Research in rodents indicates that weight loss is able to improve insulin sensitivity of the brain. The current project will test this hypothesis in humans. Therefore, brain insulin sensitivity will be assessed by fMRI in combination with intranasal insulin administration, using an established protocol. Furthermore, effects of daily administration of insulin nasal spray (versus placebo) over 8 weeks will be assessed as secondary (exploratory) variables.

03

Conditions studied

  • Insulin Resistance

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \<6.5%
  • Age between 40 and 75 years
  • No intake of antidiabetic drugs or drugs for weight reduction
  • no intake
  • Stable medication over 10 weeks before the start of the study

Exclusion criteria

Exclusion Criteria:

  • Persons who wear non-removable metal parts in or on the body.
  • Persons with reduced temperature sensitivity and / or increased sensitivity to heating of the body
  • Cardiovascular disease can not be ruled out, e.g. manifest coronary heart disease, heart failure greater than 2, previous heart attack, stroke condition
  • Persons with hearing impairment or increased sensitivity to loud noises
  • People with claustrophobia
  • Minors or non-consenting subjects are also excluded
  • Subjects with an operation less than 3 months
  • Simultaneous participation in other studies
  • Neurological and psychiatric disorders
  • Subjects with Hb \<11 g / dl
  • to any of the substances used
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    nasal insulin

    daily administration of 160 U of human insulin as nasal spray

    Other: nasal insulin

  • Placebo comparator
    placebo spray

    daily administration of placebo solution as nasal spray

    Other: placebo spray

Interventions

  • Othernasal insulin
  • Otherplacebo spray
06

What researchers measure

Primary outcomes

  1. brain insulin sensitivity

    fMRI measurement will be performed before and after administration of 160 U of human insulin as nasal spray. Changes in regional activity will be quantified to assess regional brain insulin sensitivity.

    Time frame: 30 minutes after administration of nasal insulin

Secondary outcomes

  1. Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on body weight.

    Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks body weight will be recorded.

    Time frame: 8 weeks

  2. Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on glucose tolerance .

    Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks glucose tolerance will be assessed using a 75 g oral glucose tolerance test.

    Time frame: 8 weeks

  3. Effect of daily administration of 160 U nasal insulin or placebo over 8 weeks on body composition .

    Participants will receive nasal insulin or placebo in a double-blind randomized fashion. Before and after 8 weeks body composition will be addressed by whole-body MRI and liver MRS.

    Time frame: 8 weeks

  4. whole-body insulin sensitivity

    Insulin sensitivity will be estimated from a frequent-sampling 75 g oral glucose tolerance test using the Matsuda formula.

    Time frame: 2 hours

  5. Glucose tolerance

    a 75 g oral glucose tolerance test will be performed. Glucose tolerance will be defined by the American Diabetes Association criteria.

    Time frame: 2 hours

  6. Cognitive function

    cognitive function will be addressed by neuropsychological testing.

    Time frame: 1 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Sep 2024, 93 months after the start.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 93 months is above that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 13, 2016
StartActual
Dec 2016
Primary completionEst.
Sep 2024
CompletionEst.
Dec 2024
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02991365
Responsible party
Sponsor
First posted
Dec 13, 2016
Start date
Dec 2016
Primary completion
Sep 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Feb 2, 2024

Study contacts

Andreas Fritsche, MD
Contact
andreas.fritsche@med.uni-tuebingen.de
+49 7071 29 80687
Andreas Fritsche, MD
principal investigator · University of Tübingen Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion